Puma Biotechnology (PBYI) Releases Q4 2025 Earnings: Revenue Beats, EPS Tops Estimates but Cash Falls

By: Quiver EarningsTracker

Posted: 1 month ago / Feb. 26, 2026 10:18 p.m. UTC

PBYI

Puma Biotechnology Inc (PBYI) — fourth-quarter 2025 highlights:

Revenue: $75.5 million (up 27.7% year-over-year; estimate $70.0 million)

Gross profit: $52.3 million (up 15.9% YoY)

Operating profit: $17.1 million (up 28.0% YoY)

Net income attributable to common shareholders: $13.4 million (down 30.4% YoY)

Diluted earnings per share: $0.26 (down 35.0% YoY; estimate $0.23)

Cost of sales: $23.1 million (up 66.1% YoY)

Cash from operating activities: $14.4 million (down 7.6% YoY)

Purchases of property, plant and equipment: $36,000 (down 325.0% YoY)

Cash and cash equivalents: $29.6 million (down 57.2% YoY)

Total liabilities: $86.0 million (down 29.1% YoY)

Puma delivered a solid top-line beat with strong revenue growth and an EPS result above estimates, while underlying profitability and cash balances showed mixed year-over-year trends.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Puma Biotechnology Inc Insider Trading Activity

Puma Biotechnology Inc insiders have traded $PBYI stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $PBYI stock by insiders over the last 6 months:

ALAN H AUERBACH (President and CEO) has made 0 purchases and 2 sales selling 34,950 shares for an estimated $204,878.
MICHAEL PATRICK MILLER sold 20,000 shares for an estimated $97,228
MAXIMO F NOUGUES (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,945 shares for an estimated $64,186.
DOUGLAS M HUNT (See Remarks) has made 0 purchases and 2 sales selling 8,987 shares for an estimated $52,695.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

Puma Biotechnology Inc Hedge Fund Activity

We have seen 82 institutional investors add shares of Puma Biotechnology Inc stock to their portfolio, and 60 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANUS HENDERSON GROUP PLC removed 745,541 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,958,822
RUSSELL INVESTMENTS GROUP, LTD. removed 713,040 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $4,242,588
GOLDMAN SACHS GROUP INC added 559,345 shares (+238.4%) to their portfolio in Q4 2025, for an estimated $3,328,102
MARSHALL WACE, LLP removed 557,548 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,317,410
AQR CAPITAL MANAGEMENT LLC added 535,933 shares (+410.1%) to their portfolio in Q4 2025, for an estimated $3,188,801
BRIDGEWAY CAPITAL MANAGEMENT, LLC added 339,924 shares (+78.4%) to their portfolio in Q4 2025, for an estimated $2,022,547
O'SHAUGHNESSY ASSET MANAGEMENT, LLC added 292,108 shares (+35.3%) to their portfolio in Q4 2025, for an estimated $1,738,042

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.